Mira Pharmaceuticals (MIRA) EPS (Basic) (2024 - 2025)
Mira Pharmaceuticals (MIRA) posted EPS (Basic) of -$0.25 for Q4 2025, up 78.55% sequentially from -$1.18 in Q3 2025, and down 62.52% YoY from -$0.67 in Q4 2024.
Mira Pharmaceuticals (MIRA) EPS (Basic) (2024 - 2025) Analysis & Trends
Mira Pharmaceuticals has reported EPS (Basic) for 2 years, with the latest figure at -$0.25 in Q4 2025.
- Quarterly EPS (Basic) fell 62.52% year-over-year to -$0.25 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was -$1.21 (down 320.66% YoY) and the FY2025 annual result came in at -$1.35, down 165.61% from the prior year.
- EPS (Basic) grew to -$0.25 in Q4 2025 per MIRA's latest filing, from -$1.18 in the prior quarter.
- Over five years, EPS (Basic) peaked at -$0.14 in Q3 2024 and troughed at -$1.18 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EPS (Basic) (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 652.20 Bn | 631.44 Bn | 17.26 Bn | 2.30 |
| 2 | AbbVie | 469.51 Bn | 462.94 Bn | 12.70 Bn | 2.04 |
| 3 | Merck | 376.81 Bn | 369.67 Bn | 12.21 Bn | -0.54 |
| 4 | Novartis Ag | 303.04 Bn | 295.35 Bn | 11.24 Bn | 1.71 |
| 5 | Astrazeneca | 257.61 Bn | 252.71 Bn | 12.86 Bn | 1.62 |
| 6 | Amgen | 237.37 Bn | 223.38 Bn | 7.24 Bn | 4.40 |
| 7 | Gilead Sciences | 181.73 Bn | 178.55 Bn | 6.22 Bn | -8.44 |
| 8 | Pfizer | 159.66 Bn | 147.96 Bn | 10.94 Bn | -0.04 |
| 9 | Gsk | 106.24 Bn | 102.07 Bn | 8.24 Bn | 0.29 |
| 10 | Mira Pharmaceuticals | 18.47 Mn | 7.44 Mn | - | -0.25 |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -0.25 |
| Sep 30, 2025 | -1.18 |
| Dec 31, 2024 | -0.16 |
| Sep 30, 2024 | -0.14 |